Jacksonville, FLORIDA10 Active Studies

Multiple Myeloma Clinical Trials in Jacksonville, FLORIDA

Find 10 actively recruiting multiple myeloma clinical trials in Jacksonville, FLORIDA. Connect with local research sites and explore new treatment options.

10
Active Trials
10
Sponsors
22,231
Enrolling

Recruiting Multiple Myeloma Studies in Jacksonville

RecruitingJacksonville, FLORIDANCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

20,000 participants
UMC Utrecht
View Study Details
RecruitingJacksonville, FLORIDANCT05827016

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly dia...

1,216 participants
Bristol-Myers Squibb
View Study Details
RecruitingJacksonville, FLORIDANCT06158841

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...

380 participants
AbbVie
View Study Details
RecruitingJacksonville, FLORIDANCT06297226

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma....

175 participants
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
View Study Details
RecruitingJacksonville, FLORIDANCT04119050

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA)....

111 participants
Janssen Research & Development, LLC
View Study Details
RecruitingJacksonville, FLORIDANCT04942067

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractor...

108 participants
Ascentage Pharma Group Inc.
View Study Details
RecruitingJacksonville, FLORIDANCT05850234

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

80 participants
AstraZeneca
View Study Details
RecruitingJacksonville, FLORIDANCT05497804

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalid...

75 participants
Mayo Clinic
View Study Details
RecruitingJacksonville, FLORIDANCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingJacksonville, FLORIDANCT06798012

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

36 participants
Takeda
View Study Details

About Multiple Myeloma Clinical Trials in Jacksonville

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 10 multiple myeloma clinical trials recruiting participants in Jacksonville, FLORIDA. These studies are seeking a combined 22,231 participants. Research is being sponsored by UMC Utrecht, Bristol-Myers Squibb, AbbVie and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Jacksonville — FAQ

Are there multiple myeloma clinical trials in Jacksonville?

Yes, there are 10 multiple myeloma clinical trials currently recruiting in Jacksonville, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Jacksonville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jacksonville research site will contact you about next steps.

Are clinical trials in Jacksonville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jacksonville studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 10 active trials in Jacksonville are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated March 2, 2026 from ClinicalTrials.gov